共 84 条
[11]
Abdel-Moneim A(2018)) J Hepatol 68 217-219
[12]
Ramadan SH(2017)Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4 Liver Int 37 5-18
[13]
Lawitz E(2016)A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure J Hepatol 66 153-194
[14]
Mangia A(2005)Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection Hepatology 43 1317-1325
[15]
Wyles D(2007)Recommendations on treatment of hepatitis C J Gen Virol 88 1526-1531
[16]
Leroy V(2013)Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection Proc Natl Acad Sci USA 110 3991-3996
[17]
Angus P(2016)Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma MOJ Immunol 4 00114-5163
[18]
Bronowicki JP(2014)Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Antimicrob Agents Chemother 58 5155-7320
[19]
Amano M(2011)Mechanisms of virologic failure in hepatitis C and strategies for treatment failure J Virol 85 7312-1590
[20]
Ishikawa H(2012)Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity Antimicrob Agents Chemother 56 1588-221